Q-omics provides the consensus-scored LRRC39 profile across patient tissues and cancer cell-line models. LRRC39 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRRC39 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LRRC39 RNA expression shows 19,372 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where LRRC39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC39 survival associations across molecular data types. LRRC39 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC39 RNA expression–survival associations across cancer types. High LRRC39 expression shows unfavorable associations in UVM, CESC, KIRC, LGG and PRAD, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for LRRC39 RNA expression.
This table summarizes LRRC39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC39 shows lower tumor expression in HNSC and higher tumor expression in KIRC, LIHC, STAD, CHOL and KIRP. The KIRC box plot shows higher LRRC39 RNA expression in tumor versus normal tissue (log2 FC = +0.383, t-test p < 0.001).
This table shows molecular features associated with LRRC39 in patient tissues and cancer cell lines. In patient samples, LRRC39 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
